Company intelligence / Profile preview

Pelvalon

Santa Clara, California, United Stateslaborie.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

The Eclipse System, a non-surgical vaginal insert for women with fecal incontinence, demonstrated high efficacy and safety in clinical studies. In a study of 61 women, 86% reported improvement after one month; another report cites 79% efficacy with no serious device-related adverse events. The product has FDA clearance and established reimbursement.

Therapeutic areas: Gastroenterology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Eclipse System

Commercial

Indications: Fecal incontinence

Partnerships

No major disclosed partnerships outside acquisition by Laborie.

Beyond the preview

Go deeper on Pelvalon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pelvalon.

Explore the full profile